Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-138495 · Präparat HOS-098200
15
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical Co-administration is
considerations, Symtuza is contraindicated (see section 4.3).
expected to increase the exposure
of lomitapide when co-
administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Cimetidine Based on theoretical Symtuza can be co-administered
Famotidine considerations, no mechanistic with H2-receptor antagonists
Nizatidine interaction is expected. without dose adjustments.
Ranitidine
IMMUNOSUPPRESSANTS
Ciclosporin Based on theoretical considerations Concentration monitoring of the
Sirolimus DRV/COBI is expected to increase immunosuppressive agent must
Tacrolimus these immunosuppressant plasma be done when co-administration
concentrations. with Symtuza occurs.
(CYP3A inhibition)
Co-administration of ciclosporin is
expected to increase plasma
concentrations of tenofovir
alafenamide.
(P-gp inhibition) Concomitant use of everolimus
Everolimus and Symtuza is not
recommended.
INHALED BETA AGONISTS
Salmeterol Based on theoretical considerations
Concomitant use of salmeterol
DRV/COBI is expected to increase
and Symtuza is not
salmeterol plasma concentrations.
recommended. The combination
(CYP3A inhibition) may result in increased risk of
cardiovascular adverse events
with salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
NARCOTIC ANALGESICS/TREATMENT OF OPIOID DEPENDENCE
Buprenorphine/naloxone Based on theoretical considerations Dose adjustment for
DRV/COBI may increase buprenorphine may not be
buprenorphine and/or necessary when co-administered
norbuprenorphine plasma with Symtuza, but a careful
concentrations. clinical monitoring for signs of
opiate toxicity is recommended.
Methadone Based on theoretical considerations No adjustment of methadone dose
DRV/COBI may increase is expected when initiating
methadone plasma concentrations. co-administration with Symtuza.
Clinical monitoring is
With ritonavir-boosted darunavir, a recommended, as maintenance
small decrease in methadone therapy may need to be adjusted
plasma concentrations was in some patients.
observed. Consult the Summary of
Product Characteristics for
darunavir for further details.
Fentanyl Based on theoretical considerations Clinical monitoring is
Oxycodone DRV/COBI may increase plasma recommended when
Tramadol concentrations of these analgesics. co-administering Symtuza with
(CYP2D6 and/or CYP3A these analgesics.
inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) nizatidine (HOS-138496) methadone (HOS-086198) cimetidine (HOS-085835) lomitapide (HOS-086160) oxycodone (HOS-109487) famotidine (HOS-112087) buprenorphine (HOS-086193) salmeterol (HOS-086285) tacrolimus (HOS-085202) ranitidine (HOS-085660) everolimus (HOS-086310) naloxone (HOS-109490) sirolimus (HOS-085172) fentanyl (HOS-086196) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 65d1745e79031f8ffd732f400ccf71034e05cacd98fcfff4372c4246da9af398 · Zeichen 33001–37311 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138690 · Präparat HOS-098240
Lansoprazole Rilpivirine
Rabeprazole Not studied. Significant
Pantoprazole decreases in rilpivirine
Esomeprazole/ plasma concentrations are
Rilpivirine expected
(reduced absorption due to
gastric pH increase).
H2-recepter antagonists
Famotidine Dolutegravir The combination of dolutegravir/rilpivirine and
Cimetidine (Not studied) H2-receptor antagonists should be used with
Nizatidine particular caution. Only H2-receptor antagonists
Ranitidine/ that can be dosed once daily should be used.
Dolutegravir
H2-receptor antagonists should be taken well
Famotidine/ Rilpivirine separated in time from the administration of
Rilpivirine1,2 AUC ↓ 9% dolutegravir/rilpivirine (minimum 4 hours after or
40 mg single dose Cmin NA 12 hours before)
taken 12 hours before Cmax ↔
rilpivirine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) nizatidine (HOS-138496) rabeprazole (HOS-114843) esomeprazole (HOS-087944) cimetidine (HOS-085835) pantoprazole (HOS-085167) famotidine (HOS-112087) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage ea9028ca3d0fa3d4c503c1b3af0236bf88a7f581c3738dab63a63d57e45bc310 · Zeichen 15199–16371 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138691 · Präparat HOS-098240
Famotidine/ Rilpivirine
Rilpivirine1,2 AUC ↓ 76%
40 mg single dose Cmin NA
taken 2 hours before Cmax ↓ 85%
rilpivirine (reduced absorption due to
gastric pH increase).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 6b69892b7e6cf20bfbf126833f69be12b63eb8ee43befd1045de7a948d03f986 · Zeichen 16373–16612 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138692 · Präparat HOS-098240
Famotidine/ Rilpivirine
Rilpivirine1,2 AUC ↑ 13%
40 mg single dose Cmin NA
taken 4 hours after Cmax ↑ 21%
rilpivirine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage ad8c90cd75b842ceef79ad44650ee9ae43ff53d282cd8d75d7848d30d6866ff6 · Zeichen 16614–16765 im Abschnitt
Wechselwirkungen · Biktarvy
Biktarvy 30 mg/120 mg/15 mg film-coated tablets Biktarvy 50 mg/200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-139309 · Präparat HOS-098314
Based on drug interaction studies conducted with Biktarvy or the components of Biktarvy, no
clinically significant drug interactions are expected with: amlodipine, atorvastatin, buprenorphine,
drospirenone, famciclovir, famotidine, fluticasone, methadone, naloxone, norbuprenorphine,
omeprazole or rosuvastatin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famciclovir (HOS-112681) fluticasone (HOS-108914) methadone (HOS-086198) atorvastatin (HOS-086304) amlodipine (HOS-086287) rosuvastatin (HOS-086307) famotidine (HOS-112087) buprenorphine (HOS-086193) drospirenone (HOS-116422) naloxone (HOS-109490) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T17:05:00Z · SHA-256 8ec4738243d92aa421e74b71a9bad453e15421c1f952d3be4e88479f189e0fe4 · Passage 82df41364d1ced0b9360d1c6e32f944053871e072fdb4f969a869fce28d6641f · Zeichen 24948–25259 im Abschnitt
Wechselwirkungen · Calquence
Calquence 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 9–10
HOS-145981 · Präparat HOS-099443
Acalabrutinib solubility decreases with increasing pH. Co-administration of acalabrutinib with an antacid
(1 g calcium carbonate) decreased acalabrutinib AUC by 53% in healthy subjects. Co-administration with
a proton pump inhibitor (40 mg omeprazole for 5 days) decreased acalabrutinib AUC by 43%.
9
If treatment with an acid reducing agent is required, consider using an antacid (e.g., calcium carbonate), or
an H2-receptor antagonist (e.g., ranitidine or famotidine). For use with antacids, the interval between
taking the medicinal products should be at least 2 hours (see section 4.2). For H2-receptor antagonists,
Calquence should be taken 2 hours before (or 10 hours after) taking the H2-receptor antagonist.
Due to the long-lasting effect of proton pump inhibitors, separation of doses with proton pump inhibitors
may not eliminate the interaction with Calquence and therefore concomitant use should be avoided (see
section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) ranitidine (HOS-085660) acalabrutinib (HOS-145966) calcium carbonate (HOS-088370) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T14:45:00Z · SHA-256 23823231ddd2d9d6c6ed4788276579f41dd0c4dfc8ca67fef193be872eb62325 · Passage c5667db7f34f0512629d7ec57c7e964b709394ed125a64f8b24f7a311bf09209 · Zeichen 1881–2872 im Abschnitt
Wechselwirkungen · Apixaban Accord
Apixaban Accord 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-146639 · Präparat HOS-099542
Other concomitant therapies
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when
apixaban was coadministered with atenolol or famotidine. Coadministration of apixaban 10 mg with
atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban.
Following administration of the two medicinal products together, mean apixaban AUC and Cmax were
15% and 18% lower than when administered alone. The administration of apixaban 10 mg with
famotidine 40 mg had no effect on apixaban AUC or Cmax.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T13:45:00Z · SHA-256 d61ca619dbc3cc41b936fd00150a7483792c8b53e4c986c4c86af1cceab6e2ab · Passage a7bcd09ec225a04d837765a5b9389e3926aa3b31b0d863f595085a029dde5249 · Zeichen 5047–5602 im Abschnitt
Wechselwirkungen · Apixaban Accord
Apixaban Accord 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 44
HOS-146683 · Präparat HOS-099542
Other concomitant therapies
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when
apixaban was coadministered with atenolol or famotidine. Coadministration of apixaban 10 mg with
atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban.
Following administration of the two medicinal products together, mean apixaban AUC and Cmax were
15% and 18% lower than when administered alone. The administration of apixaban 10 mg with
famotidine 40 mg had no effect on apixaban AUC or Cmax.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atenolol (HOS-087794) famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T13:45:00Z · SHA-256 d61ca619dbc3cc41b936fd00150a7483792c8b53e4c986c4c86af1cceab6e2ab · Passage a7bcd09ec225a04d837765a5b9389e3926aa3b31b0d863f595085a029dde5249 · Zeichen 4975–5530 im Abschnitt
Wechselwirkungen · Cibinqo
Cibinqo 50 mg film-coated tablets Cibinqo 100 mg film-coated tablets Cibinqo 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-147560 · Präparat HOS-099686
When abrocitinib 200 mg was administered concomitantly with famotidine 40 mg, an H2-receptor
antagonist, abrocitinib active moiety exposures decreased by approximately 35%. The effect of
elevating gastric pH with antacids, or proton pump inhibitors (omeprazole) on the pharmacokinetics of
abrocitinib has not been studied and may be similar to that seen with famotidine. The higher 200 mg
daily dose should be considered for patients treated concomitantly with products which increase
gastric pH, as they may reduce the efficacy of abrocitinib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-16T15:51:00Z · SHA-256 bdf6a4ed1027bc748659bcb0a96655dbad2dd1f8fd77f49e5ad43eff208cc7ff · Passage 83954a75f851d216bb4460db9e87fcbbfe641a9fff6c95afe7bef44a189d2a2d · Zeichen 1584–2128 im Abschnitt
Wechselwirkungen · Lumykras
LUMYKRAS 120 mg film-coated tablets LUMYKRAS 240 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-147835 · Präparat HOS-099774
Acid-reducing agents
Co-administration of sotorasib with a PPI (omeprazole) or an H2 receptor antagonist (famotidine) led
to a decrease in sotorasib concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-08T15:18:00Z · SHA-256 3def3e20469c47be2c1e0dc423ffbd7ecccc89e51d789879090c1b435792befd · Passage 58367dd0658a61fec3fb8f1dd8b6e301405a56fd4a082f84369e620b6ea9b18a · Zeichen 510–674 im Abschnitt
Wechselwirkungen · Lumykras
LUMYKRAS 120 mg film-coated tablets LUMYKRAS 240 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-147836 · Präparat HOS-099774
Under fed conditions (standard-calorie moderate-fat meals), co-administration of multiple doses of
omeprazole with a single dose of 960 mg sotorasib decreased sotorasib Cmax by 65% and area under
the curve (AUC) by 57%. Co-administration of a single dose of famotidine given 10 hours prior and
2 hours after a single dose of 960 mg sotorasib decreased sotorasib Cmax by 35% and AUC by 38%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-08T15:18:00Z · SHA-256 3def3e20469c47be2c1e0dc423ffbd7ecccc89e51d789879090c1b435792befd · Passage 3d6265fa56fe954e5cc297430be3b0235cb1dce7a9df369b1e52226ab0a09b07 · Zeichen 676–1065 im Abschnitt
Wechselwirkungen · Pyrukynd
Pyrukynd 5 mg film-coated tablets Pyrukynd 20 mg film-coated tablets Pyrukynd 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-147886 · Präparat HOS-099782
Gastric acid-reducing agents
Mitapivat exhibits pH-dependent solubility (see section 5.2) and coadministration with gastric
acid-reducing agents (e.g. famotidine) may decrease mitapivat absorption (see section 4.4).
Concomitant use of mitapivat with medicinal products that elevate gastric pH was not evaluated in a
clinical drug-drug interaction study. If concomitant use of gastric acid-reducing agents is unavoidable,
patients should be monitored for reduced efficacy of mitapivat.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T11:25:00Z · SHA-256 03d501776d0624826818135ad3ead3dbd02ded30f25a5a3920a5a762850351f5 · Passage 5c7649aee0ad7ee86bc2d76eaf740671c2c252c2277d49760facd9cc5af9d138 · Zeichen 1483–1967 im Abschnitt
Wechselwirkungen · Quviviq
QUVIVIQ 25 mg film-coated tablets QUVIVIQ 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-148256 · Präparat HOS-099866
Gastric pH-modifiers
The solubility of daridorexant is pH-dependent. In healthy subjects, co-administration with famotidine
(40 mg), an inhibitor of gastric acid secretion, decreased daridorexant Cmax by 39% while AUC
remained unchanged.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-12T16:40:00Z · SHA-256 5355155af856aafb53e689e2fbc2ec06efe5415b8ac06dc050f95e8259efdb63 · Passage 3f0afc4c89e1cee476a7eafa21ea583815cdc77121a98c388cf5c9aff6043e82 · Zeichen 1118–1355 im Abschnitt
Wechselwirkungen · Sunlenca
Sunlenca 464 mg solution for injection · Abschnitt 4.5 · PDF-Seite 8
HOS-148312 · Präparat HOS-099874
Plasma concentration of triazolam
may be increased when
co-administered with lenacapavir.
ANTICOAGULANTS
Direct Oral Anticoagulants Interaction not studied. Due to potential bleeding risk, dose
(DOACs) adjustment of DOAC may be
Rivaroxaban Plasma concentration of DOAC required. Consult the Summary of
Dabigatran may be increased when Product Characteristics of the
Edoxaban co-administered with lenacapavir. DOAC for further information on
use in combination with moderate
CYP3A inhibitors and/or P-gp
inhibitors.
ANTIFUNGALS
Voriconazolea,b,p,q (400 mg twice Lenacapavir: No dose adjustment of lenacapavir
daily/200 mg twice daily) AUC:↑ 41% is required.
Cmax:↔
Itraconazole Interaction not studied.
Ketoconazole
Plasma concentration of
lenacapavir may be increased when
co-administered with itraconazole
or ketoconazole.
H2-RECEPTOR ANTAGONISTS
Famotidinea,b (40 mg once daily, 2 Famotidine: No dose adjustment of famotidine
hours before lenacapavir) AUC:↑ 28% is required.
Cmax:↔
ORAL CONTRACEPTIVES
Ethinylestradiol Interaction not studied. No dose adjustment of
Progestins ethinylestradiol and progestins is
Plasma concentrations of required.
ethinylestradiol and progestins may
be increased when co-administered
with lenacapavir.
GENDER AFFIRMING HORMONES
17β-estradiol Interaction not studied. No dose adjustment of these gender
Anti-androgens affirming hormones is required.
Progestogen Plasma concentrations of these
Testosterone medicinal products may be
increased when co-administered
with lenacapavir.
a Fasted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) estradiol (HOS-090751) famotidine (HOS-112087) dabigatran (HOS-112096) rivaroxaban (HOS-086236) itraconazole (HOS-084516) testosterone (HOS-144014) edoxaban (HOS-086234) triazolam (HOS-086168)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T15:19:00Z · SHA-256 5e82373c9638ee4d24450180684e7d233b6a19a1b3755e36a56d1822304f7bda · Passage a915a1f657da45e33267987d7967f31e6736f67e9519d8f4311b625f3e788fd3 · Zeichen 13054–15835 im Abschnitt
Wechselwirkungen · Sunlenca
Sunlenca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 24–25
HOS-148345 · Präparat HOS-099874
24
Medicinal product by therapeutic Effects on concentrations. Recommendation concerning
areas Mean percent change in AUC, co-administration with Sunlenca
Cmax
Rivaroxaban Plasma concentration of DOAC required. Consult the Summary of
Dabigatran may be increased when Product Characteristics of the
Edoxaban co-administered with lenacapavir. DOAC for further information on
use in combination with moderate
CYP3A inhibitors and/or P-gp
inhibitors.
ANTIFUNGALS
Voriconazolea,b,p,q (400 mg twice Lenacapavir: No dose adjustment of lenacapavir
daily/200 mg twice daily) AUC:↑ 41% is required.
Cmax:↔
Itraconazole Interaction not studied.
Ketoconazole
Plasma concentration of
lenacapavir may be increased when
co-administered with itraconazole
or ketoconazole.
H2-RECEPTOR ANTAGONISTS
Famotidinea,b (40 mg once daily, 2 Famotidine: No dose adjustment of famotidine
hours before lenacapavir) AUC:↑ 28% is required.
Cmax:↔
ORAL CONTRACEPTIVES
Ethinylestradiol Interaction not studied. No dose adjustment of
Progestins ethinylestradiol and progestins is
Plasma concentrations of required.
ethinylestradiol and progestins may
be increased when co-administered
with lenacapavir.
GENDER AFFIRMING HORMONES
17β-estradiol Interaction not studied. No dose adjustment of these gender
Anti-androgens affirming hormones is required.
Progestogen Plasma concentrations of these
Testosterone medicinal products may be
increased when co-administered
with lenacapavir.
a Fasted.
b This study was conducted using lenacapavir 300 mg single dose administered orally.
c Evaluated as a strong inducer of CYP3A, and an inducer of P-gp and UGT.
d Fed.
e Evaluated as a strong inhibitor of CYP3A, and an inhibitor UGT1A1 and P-gp.
f Evaluated as a moderate inducer of CYP3A and an inducer of P-gp.
g Evaluated as a strong inhibitor of CYP3A and an inhibitor of P-gp.
h Evaluated as a strong inhibitor of CYP3A, and an inhibitor and inducer of P-gp.
i This study was conducted using lenacapavir 600 mg single dose following a loading regimen of 600 mg twice daily for 2
days, single 600 mg doses of lenacapavir were administered with each co-administered medicinal product.
j Evaluated as a P-gp substrate.
k Tenofovir alafenamide is converted to tenofovir in vivo.
l Evaluated as an OATP substrate.
m Evaluated as an BCRP substrate.
n Evaluated as a CYP3A substrate.
o Major active metabolite of midazolam.
p Evaluated as a strong inhibitor of CYP3A.
q This study was conducted using voriconazole 400 mg loading dose twice daily for a day, followed by 200 mg
maintenance dose twice daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) ketoconazole (HOS-084513) tenofovir alafenamide (HOS-110476) estradiol (HOS-090751) famotidine (HOS-112087) dabigatran (HOS-112096) rivaroxaban (HOS-086236) voriconazole (HOS-084524) itraconazole (HOS-084516) testosterone (HOS-144014) edoxaban (HOS-086234) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T15:19:00Z · SHA-256 5e82373c9638ee4d24450180684e7d233b6a19a1b3755e36a56d1822304f7bda · Passage 7b7db1f59ada26cdb5d11adfd5d80c27fae528ed5d6be0bb7ca147ee4f647c81 · Zeichen 13431–17331 im Abschnitt
Wechselwirkungen · Sotyktu
SOTYKTU 6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-149256 · Präparat HOS-100020
Medicinal products that are inhibitors or inducers of CYP enzymes or transporters such as
cyclosporine (dual P-gp/breast cancer resistance protein [BCRP] inhibitor), fluvoxamine (strong
CYP 1A2 inhibitor), ritonavir (moderate CYP 1A2 inducer), diflunisal (UGT 1A9 inhibitor),
pyrimethamine (OCT1 inhibitor), famotidine (H2 receptor antagonist) or rabeprazole (proton pump
inhibitor) do not meaningfully affect plasma deucravacitinib exposures (see section 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rabeprazole (HOS-114843) famotidine (HOS-112087) diflunisal (HOS-127089) ritonavir (HOS-084521) fluvoxamine (HOS-085908) pyrimethamine (HOS-088523) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T18:15:00Z · SHA-256 9ba2af895eb769b0e134e9b62a0e549462d3c3401ee20e2f9d271718a8dad081 · Passage 84326d04fd5262ff93b11039d13229179c5aa7006e8a9a4f808e14fec001f5f9 · Zeichen 758–1219 im Abschnitt
Wechselwirkungen · Aquipta
AQUIPTA 10 mg tablets AQUIPTA 60 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-149992 · Präparat HOS-100196
Co-administration of atogepant with oral contraceptive components ethinyl estradiol and
levonorgestrel, paracetamol, naproxen, sumatriptan, or ubrogepant did not result in significant
pharmacokinetic interactions for either atogepant or co-administered medicinal products. Co-
administration with famotidine or esomeprazole did not result in clinically relevant changes of
atogepant exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): esomeprazole (HOS-087944) levonorgestrel (HOS-089677) sumatriptan (HOS-128726) famotidine (HOS-112087) ethinyl estradiol (HOS-088135) ubrogepant (HOS-149993) naproxen (HOS-087936)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T13:51:04Z · SHA-256 9d42d1f3230d786a522a366a7a9d9a4e1b16d695023c0280fdc3a58f424c9dba · Passage ad6d234cabdc4ffb99ef6e53548008edc613e8fb47ce1a20359f64933df542b2 · Zeichen 890–1282 im Abschnitt
Wechselwirkungen · Joenja
Joenja 70 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-150276 · Präparat HOS-100280
OAT3 substrates
Leniolisib is an OAT3 inhibitor and may increase systemic exposure to OAT3 substrates (e.g.,
adefovir, baricitinib, bumetanide, cefaclor, ceftizoxime, ciprofloxacin, famotidine, furosemide,
methotrexate, oseltamivir carboxylate, benzylpenicillin [penicillin G], tenofovir). When co-
administered, leniolisib increased furosemide exposure 1.4-fold. Avoid concomitant use of leniolisib
with medicinal products that are OAT3 substrates with a narrow therapeutic index (e.g., methotrexate).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) furosemide (HOS-089060) baricitinib (HOS-134782) ceftizoxime (HOS-150279) oseltamivir carboxylate (HOS-150280) ciprofloxacin (HOS-085177) adefovir (HOS-088122) famotidine (HOS-112087) bumetanide (HOS-125088) cefaclor (HOS-089670) penicillin G (HOS-121627) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-25T08:30:00Z · SHA-256 86ff542b4d3f7d0061b00035c52721373fd7e4b34a35a937a43304ec20dbf3fd · Passage 82c0b129f5af4a5f57d4345b42d8969f17289c7d066c02b31b95cc7f6eda6fc9 · Zeichen 2334–2836 im Abschnitt
Wechselwirkungen · Wayrilz
WAYRILZ 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-152880 · Präparat HOS-100859
Rilzabrutinib solubility decreases with increasing pH. Co-administration with a PPI (esomeprazole)
decreased rilzabrutinib AUC by 51% in healthy subjects. Co-administration of rilzabrutinib with a
H2RA (famotidine) reduced rilzabrutinib AUC by approximately 36% and no significant change was
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): esomeprazole (HOS-087944) famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T12:55:15Z · SHA-256 4eba34288fff577005fcc872b421b07eb340a9df980774bd86c62c0a78638c5d · Passage aa97b5e620969d53fcd51bf92f7e41fe70daa1c6fb9b27f9d2b03fa7fb29fee1 · Zeichen 1952–2243 im Abschnitt
Wechselwirkungen · Wayrilz
WAYRILZ 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-152883 · Präparat HOS-100859
5
observed in rilzabrutinib exposure if rilzabrutinib was administered at least 2 hours prior to
famotidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T12:55:15Z · SHA-256 4eba34288fff577005fcc872b421b07eb340a9df980774bd86c62c0a78638c5d · Passage 7b9adb57b9b4738f5065ac8031e03977728a2be31466ab0902dec3b3b2792d4c · Zeichen 2297–2406 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.